Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Örbom

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|July 17, 2023
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [<sup>177</sup>Lu]Lu-PSMA-617 therapy in an animal model of prostate cancerAyman Abouzayed, Wahed Zedan, Mohamed Altai, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
Kidney Protection with the Radical Scavenger α<sub>1</sub>-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand TherapyAmanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, et al.
Scientific Reports|May 11, 2024
Hematological and renal toxicity in mice after three cycles of high activity [<sup>177</sup>Lu]Lu-PSMA-617 with or without human α<sub>1</sub>-microglobulinAmanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 28, 2024
Intratumoral Distribution of [<sup>177</sup>Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate CancerAnders Örbom, Joanna Strand, Mohamed Altai, et al.
Pharmaceutics|April 23, 2022
Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, et al.
Frontiers in Physiology|July 9, 2020
Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by BleomycinIrma Mahmutovic Persson, Hanna Falk Håkansson, Anders Örbom, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 25, 2025
Heterogeneous Distribution and Absorbed Dose of Radiolabeled Nanoparticles and Colloids in Sentinel Lymph NodesRenata Madru, Erik Larsson, Anders Örbom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2013
The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma modelAnders Örbom, Sophie E Eriksson, Erika Elgström, et al.
Nuklearmedizin. Nuclear Medicine|March 18, 2025
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse modelAnders Örbom, Susan Evans-Axelsson, Bo Jansson, et al.
Frontiers in Medicine|April 24, 2024
<i>In vivo</i> MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycinIrma Mahmutovic Persson, Nina Fransén Petterson, Jian Liu, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Journal of Nuclear Medicine and Molecular Imaging|July 17, 2023
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [<sup>177</sup>Lu]Lu-PSMA-617 therapy in an animal model of prostate cancerAyman Abouzayed, Wahed Zedan, Mohamed Altai, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
Kidney Protection with the Radical Scavenger α<sub>1</sub>-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand TherapyAmanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, et al.
Scientific Reports|May 11, 2024
Hematological and renal toxicity in mice after three cycles of high activity [<sup>177</sup>Lu]Lu-PSMA-617 with or without human α<sub>1</sub>-microglobulinAmanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 28, 2024
Intratumoral Distribution of [<sup>177</sup>Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate CancerAnders Örbom, Joanna Strand, Mohamed Altai, et al.
Pharmaceutics|April 23, 2022
Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, et al.
Frontiers in Physiology|July 9, 2020
Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by BleomycinIrma Mahmutovic Persson, Hanna Falk Håkansson, Anders Örbom, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 25, 2025
Heterogeneous Distribution and Absorbed Dose of Radiolabeled Nanoparticles and Colloids in Sentinel Lymph NodesRenata Madru, Erik Larsson, Anders Örbom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2013
The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma modelAnders Örbom, Sophie E Eriksson, Erika Elgström, et al.
Nuklearmedizin. Nuclear Medicine|March 18, 2025
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse modelAnders Örbom, Susan Evans-Axelsson, Bo Jansson, et al.
Frontiers in Medicine|April 24, 2024
<i>In vivo</i> MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycinIrma Mahmutovic Persson, Nina Fransén Petterson, Jian Liu, et al.
Pageof 2